Difference between revisions of "Loricrin (TG3)"
(New page: {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" ! {{infobox header}}| '''{{PAGENAME}}''' |- | align="center" colspan="2...) |
|||
Line 11: | Line 11: | ||
|- | |- | ||
| Determination type | | Determination type | ||
− | | In situ | + | | In situ/In vitro |
|- | |- | ||
| Source | | Source |
Revision as of 05:55, 25 July 2007
Template:Infobox header| Loricrin (TG3) | |
---|---|
Loricrin (TG3) | |
Substrate peptide name | Loricrin (TG3) |
Synonyms | - |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Cornified envelope |
Swissprot ID | P23490 |
Reactive glutamines | Q3, Q6, Q10, Q153, Q156, Q215, Q216, Q219, Q225, Q303, Q305, Q306, Q308 |
Reactive lysines | K4, K5, K88, K307, K315 |
Substrate sequence | SYQKKQPTPQPPV
SGGSVKYSGGG FSGQAVQCQSY YVSSQQVTQTSCA APQPSYGGG CHQTQQKQAPTWPSK |
Structure | No available crystal structure |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:2007607 |
Notes | Residues in bold have been determined as in situ substrates of TG3 |
Template:Infobox header | |